ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D

At the American College of Cardiology (ACC) 2026 conference, researchers unveiled groundbreaking findings suggesting that dulaglutide, a widely used diabetes medication, may play a significant role in stabilizing coronary plaques from the inside out, in addition to its established role in managing type 2 diabetes. This revelation could have profound implications for the management of cardiovascular disease in diabetic patients, potentially offering a novel approach to reducing the risk of heart events.

Dulaglutide, a GLP-1 receptor agonist, has been prescribed for years to help regulate blood sugar levels in patients with type 2 diabetes. However, the latest study, presented at the ACC conference, reveals an unexpected benefit: its ability to stabilize coronary plaques. Previously, it was believed that medications like dulaglutide primarily acted on the surface of plaques, reducing their size or altering their composition. The new findings, however, suggest that dulaglutide may be working from the inside out, targeting the core of the plaque and preventing it from progressing into a more dangerous form.

The study, which involved a large cohort of patients with type 2 diabetes and established coronary artery disease, demonstrated that those treated with dulaglutide had a significantly lower incidence of adverse cardiovascular events compared to those on standard diabetes management. This included a reduced risk of myocardial infarction, heart failure, and other complications associated with unstable plaques. The researchers attributed this protective effect to dulaglutide's unique mechanism of action, which not only manages glucose levels but also modulates the inflammatory environment within the plaque, inhibiting the progression of atherosclerosis.

The implications of these findings are significant. Coronary plaque instability is a major contributor to heart attacks and strokes in diabetic patients, who are already at a higher risk of cardiovascular disease. By stabilizing plaques from the inside out, dulaglutide could potentially offer a new layer of protection, reducing the need for additional cardiovascular medications or procedures. This could lead to better outcomes for patients and potentially lower healthcare costs associated with managing complications of diabetes.

However, it is important to note that the study has its limitations. While the results are promising, further research is needed to confirm the exact mechanism by which dulaglutide achieves this stabilization and to determine the optimal dosing regimen. Additionally, the study population was primarily composed of patients with type 2 diabetes and established coronary artery disease, so the applicability to other patient groups or those without established disease remains to be seen.

Despite these caveats, the findings at ACC 2026 have sparked considerable interest among cardiologists and diabetologists. Many experts are calling for larger, randomized controlled trials to fully explore the potential benefits of dulaglutide in stabilizing coronary plaques. If these benefits are confirmed, dulaglutide could become an even more valuable tool in the management of diabetes and the prevention of cardiovascular disease, offering a new paradigm in the treatment of diabetic patients at high risk for heart events.

In conclusion, the presentation at ACC 2026 has shed new light on the potential cardiovascular benefits of dulaglutide, a medication primarily used to manage type 2 diabetes. The suggestion that it may stabilize coronary plaques from the inside out could revolutionize the approach to managing diabetic patients with cardiovascular risk. While further research is needed to fully understand and confirm these findings, the potential implications for patient care and outcomes are significant, offering hope for improved management of diabetes and its complications.